DWM
STOK icon

Dogwood Wealth Management’s Stoke Therapeutics STOK Stock Holding History

Dogwood Wealth Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$785 Buy
+24
New +$770 ﹤0.01% 791

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dogwood Wealth Management's STOK Position: Q2 2026 in Review

Dogwood Wealth Management opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 24 shares worth $785. The stake represents ﹤0.01% of the portfolio and ranks #791 among its holdings.

197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Dogwood Wealth Management held 24 shares of Stoke Therapeutics worth $785 as of Q2 2026.
  • Stoke Therapeutics was a new Dogwood Wealth Management position in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Dogwood Wealth Management's portfolio in Q2 2026, its #791 holding.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Dogwood Wealth Management's 13F filing for Q2 2026, filed 6 Jul 2026.